Informatie:
Fout:
ID
34421
Beschrijving
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01360554
Link
https://clinicaltrials.gov/show/NCT01360554
Trefwoorden
Versies (1)
- 17-01-19 17-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
evidence of pathologically confirmed, advanced nsclc (with known histology).
boolean
ID.2
Item
prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced nsclc).
boolean
ID.3
Item
adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.
boolean
ID.4
Item
adequate renal, hematologic, liver function.
boolean
ID.5
Item
ecog ps of 0-2.
boolean
ID.6
Item
radiologically measurable disease.
boolean
ID.7
Item
small cell histology.
boolean
ID.8
Item
symptomatic brain mets or known leptomeningeal mets.
boolean
ID.9
Item
prior therapy with agent known or proposed to be active by action on egfr tyrosine kinase or other her family proteins.
boolean
ID.10
Item
uncontrolled medical disorders.
boolean